A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder.

OBJECTIVES Until the recent approval of methylphenidate (MPH), Japan had no approved treatment for attention-deficit/hyperactivity disorder (ADHD). The need still exists for an effective, safe, nonstimulant treatment. This first placebo-controlled Japan study of an ADHD nonstimulant therapy assessed atomoxetine efficacy and safety to determine the optimal dose for controlling ADHD symptoms in children and adolescents. METHODS A total of 245 Japanese children and adolescents, aged 6-17 years and diagnosed with ADHD, were randomly assigned to receive placebo or one of three atomoxetine doses (0.5, 1.2, and 1.8 mg/kg per day) over 8 weeks. Symptoms were assessed with the Japanese Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator scored and integrated with teacher reports (ADHD RS-IV-J:I/Sch). Adverse events, vital signs, laboratory tests, and electrocardiograms (ECGs) were obtained for safety analysis. RESULTS In all, 234 patients completed the study. Atomoxetine at 1.8 mg/kg per day was significantly superior to placebo in reducing ADHD symptoms (p = 0.01; one-sided). Decreased appetite and vomiting were significantly greater in the atomoxetine treatment groups; however, no clinically significant differences were observed. Two patients discontinued due to affect lability and headache. A linear dose-response and vital signs similar to those from other atomoxetine studies were observed. CONCLUSION Atomoxetine provides an effective and safe nonstimulant option for the treatment of Japanese pediatric patients with ADHD.

[1]  Rodney J. Moore,et al.  Abuse liability assessment of atomoxetine in a drug-abusing population. , 2008, Drug and alcohol dependence.

[2]  N. Yasui-Furukori,et al.  No association between CYP2D6 polymorphisms and personality trait in Japanese. , 2007, British journal of clinical pharmacology.

[3]  Bung-Nyun Kim,et al.  Atomoxetine versus Methylphenidate in Paediatric Outpatients with Attention Deficit Hyperactivity Disorder: A Randomized, Double-Blind Comparison Trial , 2007, The Australian and New Zealand journal of psychiatry.

[4]  R. Tamura,et al.  A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[5]  A. Klassen,et al.  Health-Related Quality of Life in Children and Adolescents Who Have a Diagnosis of Attention-Deficit/Hyperactivity Disorder , 2004, Pediatrics.

[6]  J. Buitelaar,et al.  A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD , 2004, European Child & Adolescent Psychiatry.

[7]  K. Schuh,et al.  Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. , 2004, Pediatrics.

[8]  L. Matza,et al.  The Link Between Health-Related Quality of Life and Clinical Symptoms Among Children with Attention-Deficit Hyperactivity Disorder , 2004, Journal of developmental and behavioral pediatrics : JDBP.

[9]  John-Michael Sauer,et al.  Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[10]  J. Biederman,et al.  Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. , 2002, The Journal of clinical psychiatry.

[11]  J. Biederman,et al.  Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. , 2002, Pediatrics.

[12]  S. West,et al.  Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study , 2002 .

[13]  J. Gillespie,et al.  Identification of the human cytochromes P450 responsible for atomoxetine metabolism. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[14]  J. Wernicke,et al.  Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. , 2001, Pediatrics.

[15]  S. Faraone,et al.  An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. , 2001, Journal of child and adolescent psychopharmacology.

[16]  N. Ryan,et al.  Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[17]  M. Eichelbaum,et al.  Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. , 1991, DNA and cell biology.

[18]  T. Ishizaki,et al.  Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. , 1990, British journal of clinical pharmacology.

[19]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[20]  Williams Da,et al.  The comparison of several dose levels with a zero dose control. , 1972 .

[21]  Williams Da,et al.  A test for differences between treatment means when several dose levels are compared with a zero dose control. , 1971 .